IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued on Wednesday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of NASDAQ:IRIX opened at $0.99 on Wednesday. The firm has a market capitalization of $16.63 million, a price-to-earnings ratio of -1.48 and a beta of 0.94. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. The business’s 50 day simple moving average is $1.35 and its 200-day simple moving average is $1.57. IRIDEX has a 12 month low of $0.78 and a 12 month high of $3.65.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings data on Thursday, March 27th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $12.70 million during the quarter, compared to analysts’ expectations of $12.80 million. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.